Topic
Neuroendocrine Tumor (NET)
Podcasts
Tumor Board # 88Oct 30, 2026Beyond First-Line Therapy: Treatment Strategies for Advanced Neuroendocrine Tumors
Few oncologists know neuroendocrine tumors from both sides of the exam table: first as a patient diagnosed during training, and now as the doctor treating them. This physician brings both perspectives to one pressing question: when a tumor progresses on a somatostatin analog, what comes next? On this episode of BackTable Tumor Board, Dr. Aman Chauhan, a medical oncologist at UCSF, interviews Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health in Salt Lake City, about treatment strategies for advanced neuroendocrine tumors beyond first-line therapy. They start with what progression on a somatostatin analog really means, how grade, Ki-67, primary site, and the pace of liver disease shape the next step, and why observation is sometimes the right call. Dr. Lewis explains how he sets expectations for PRRT after NETTER-1 and NETTER-2, including the small but real risk of secondary myelodysplasia and leukemia.
- Tumor Board # 74Jul 28, 2026
Systemic Therapy Strategies for Treating Neuroendocrine Tumors
What first-line therapies should be considered for patients with higher-grade, metastatic neuroendocrine tumors (NETs)? In this new episode of BackTable Tumor Board, Drs. Lingling Du, Chih-Yi Liao, and Robert Ramirez discuss the use of systemic or radioligand therapies for metastatic well-differentiated NETs.
- Tumor Board # 72Jul 14, 2026
Optimizing Liver-Directed Interventions for Neuroendocrine Tumors
What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for neuroendocrine tumors? In this episode of the BackTable Tumor Board Podcast, Dr. Lingling Du, Dr. Chih-Yi Liao, and Dr. Abdul Khan discuss the structure of a multidisciplinary tumor board and how they approach decision-making for patients with neuroendocrine tumors. The conversation explores who benefits most from liver-directed therapy, optimal timing for intervention, and the importance of individualized treatment planning.
- Tumor Board # 70Jun 30, 2026
Diagnosis & Initial Management of Neuroendocrine Tumors
How do you unravel the complexity of diagnosing and managing neuroendocrine tumors, where every case demands a tailored approach? In this episode of BackTable Tumor Board, host Dr. Lingling Du is joined by Dr. Chih-Yi Liao and Dr. Xavier Keutgen to break down the essential steps from first symptoms to staging, imaging, and early treatment decisions for NET patients. The discussion covers the spectrum of NET biology, individualized imaging strategies, and when surgery or systemic therapy is the best path forward.
- Tumor Board # 50Mar 10, 2026
Beyond the Beam: Integrating Radiopharmaceuticals into Modern Oncology Practice
Though relatively new, there is a rapidly growing interest in the field of therapeutic radiopharmaceuticals and their potential to play a significant role in cancer treatment. This episode of BackTable Tumor Board covers recent developments in radiopharmaceutical therapies with radiation oncologists Dr. Dustin Boothe and Dr. Ryan Funk, where they discuss efficacy, side effects, and better tolerability of modern radiopharmaceuticals compared to older ones.
Vascular & IR # 602Dec 29, 2025Managing Neuroendocrine Tumors in Interventional Radiology
What considerations drive your decision between bland embolization, TACE, and radioembolization in managing neuroendocrine tumors? In this BackTable episode, Dr. Daniel DePietro, interventional radiologist at the University of Pennsylvania joins host Dr. Kavi Krishnasamy for an in-depth discussion on the interventional management of neuroendocrine tumors.
- Vascular & IR # 564Aug 12, 2025
Pressure-Enabled Drug Delivery in HCC & Metastatic Liver Lesions
Can you manipulate blood flow in the tumor microenvironment to optimize drug delivery? In this episode of the BackTable Podcast, interventional oncologist Dr. Zachary Berman (UC San Diego) joins host Dr. Christopher Beck to discuss real-world applications of pressure-enabled drug delivery in local, regional liver-directed therapies like TACE and Y90.
- Vascular & IR # 256Oct 28, 2022
Origins of TACE
In this episode, guest host Dr. Nicholas Fidelman interviews Dr. Michael Soulen, a key player in the development and widespread adoption of transarterial chemoembolization (TACE). The doctors discuss how TACE became a major therapeutic option for liver tumors, his preferred method of TACE dosage and management, and exciting new frontiers in chemoembolization.